Clinical Trial Search

Primary: Number of Responders at Week 3 — 4; 9; 0; 3 responders

Primary: Change in the PANSS-EC Score Among Participants From Baseline to 2 Hours After Administration of the Medication. — -11.0; -11.5 score on a scale — p=>0.05

Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — 18.0; 18.0; 17.9; -10.4 score on a scale — p=<0.0001

Primary: ADCS-Clinical Global Impression of Change in Agitation (ADCS-CGIC-A) — 3.434; 3.442 score on a scale — p=0.9904

Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — 17.5; 17.6; 17.6; -8.4 score on a scale — p=<0.0001

Primary: PANSS-EC Change From Baseline — -4.98; -6.71; -8.56 PANSS units — p=0.0880

Primary: Positive and Negative Syndrome Scale - Excited Component — 7.86; 14.93 PANSS SCORE

Primary: Change Scores for Criteria D Items on the CAPS Structured Clinical Interview — -1.20; -6.27 units on a scale — p=.27

Primary: Mean Clinical Global Impression of Change (CGIC) at Last Observation — 2.6; 4.5 units on a scale

Primary: Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score for the First Episode of Agitation — -5.7; -7.5; -5.4 score on…

Primary: Change in CMAI Total Score — -15.4; -10.0; -11.5 score on a scale — p=0.010

Primary: Change From Baseline to 2 Hours Post the First Intramuscular (IM) Injection in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) — -4.7; -4.6 units on a…

Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015

Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53

Primary: NeuroBehavior Rating Scale-- Agitation — 4.33; 5.26 units on a scale — p=0.036

Primary: The Primary Outcome Measure Was Change in a Gait Stride Length Between Groups at 12 and 27 Weeks. — 107.66; 112.29; 103.35 centimeters

Primary: Change From Baseline in Timed Up and Go (TUG) Test Time at 6 Weeks — -0.7; -1.3 change in seconds from basline

Primary: Number of Participants With Emergent Agitation — 16; 24 Participants

Primary: Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change — 2.5; 2.43 units on a scale

Primary: Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behaviour and Mood) — 2; 2 Points on a scale

Primary: Physical Activity Based on the Amount of Moderate Intensity Walking — 9.45; 16.17 minutes of moderate intensity walking

Primary: Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Scores at 72 Hours — -17.32; -18.44 scores on a scale

Primary: Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score — 73.7; 68.8; 71.3; -16.2 score on a scale — p=0.789

Primary: Change in PANSS Excited Component (PEC) Score From Baseline Following Dose #1 of Staccato Loxapine, Compared With Placebo — -4.9; -8.1; -9.0 units on a scale — p=<0.0001

Primary: Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12 — 73.9; 72.3; 71.7; -10.7 units on a…

Primary: Apathy Evaluation Scale Score at 12 Weeks — 38.2; 43.6 units on a scale — p=<0.05

Primary: Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score — -5.4; -7.1; -2.9; -6.8 score on a scale — p=0.0813

Primary: Change in PANSS-EC From Baseline — -5.5; -8.1; -8.6 units on a scale — p=0.0004

Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed

Primary: Change From Baseline (Predose) in Mean International Restless Legs Syndrome (IRLS) Rating Scale at End of Intervention Period — 20.6; 21.6; 16; 18.8 score on a scale